Clinical Trials Browser

Breast Neoplasms, Colonic Neoplasms, Esophageal Neoplasms, Head and Neck Neoplasms, Lung Neoplasms, Melanoma, Neoplasm Metastasis, Pancreatic Neoplasms, Urologic Neoplasms, Endometrial Neoplasms

NCT04837209 2025-10-01

NADiR

Phase 2 Active not recruiting

32 enrolled

Breast

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT03945721 2025-09-29

UNITY

Phase 1 Active not recruiting

21 enrolled

Breast

Breast Neoplasms, Neoplasm, Residual, Triple Negative Breast Neoplasms

NCT04641247 2025-09-29

A Long-term Treatment Extension Study of Niraparib in Participants Who Completed a Prior GlaxoSmithKline/TESARO-sponsored Niraparib Study

Phase 2 Recruiting

30 enrolled

BreastGynecologic

Breast Neoplasms, Ovarian Neoplasms

NCT04584255 2025-07-28

Niraparib + Dostarlimab In BRCA Mutated Breast Cancer

Phase 2 Active not recruiting

62 enrolled

Breast

Breast Neoplasms

NCT04915755 2025-07-16

ZEST

Phase 3 Active not recruiting

40 enrolled 13 charts

Breast

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT03329937 2025-01-08

Study Evaluating the Antitumor Activity and Safety of Niraparib as Neoadjuvant Treatment in Participants With Breast Cancer

Phase 1 Completed

21 enrolled 12 charts

Breast

Breast Neoplasms

NCT03154281 2024-08-01

Evaluation of the Safety and Tolerability of Niraparib With Everolimus in Advanced Gynecologic Malignancies and Breast

Phase 1 Completed

14 enrolled 12 charts

BreastGynecologic

Breast Neoplasms, Ovarian Neoplasms

NCT04240106 2024-02-16

LUZERN

Phase 2 Completed

14 enrolled

Breast

Breast Neoplasms

NCT05238831 2024-01-23

SMMART Adaptive Clinical Treatment (ACT) Trial

Phase EARLY_PHASE1 Withdrawn

BreastGastrointestinalGenitourinaryGynecologicSarcoma

Breast Neoplasms, Ovarian Neoplasms, Pancreatic Neoplasms, Prostatic Neoplasms, Sarcoma

NCT02657889 2022-12-01

TOPACIO

Phase 1/2 Completed

122 enrolled 29 charts

BreastGynecologic

Breast Neoplasms, Fallopian Tube Neoplasms, Neoplasms, Ovarian Neoplasms, Triple Negative Breast Neoplasms

NCT01905592 2022-11-15

BRAVO

Phase 3 Terminated

216 enrolled 19 charts

BreastGynecologic

Breast Neoplasms, Ovarian Neoplasms

NCT02826512 2022-07-18

A Feasibility Study of Niraparib for Advanced, BRCA1-like, HER2-negative Breast Cancer Patients

Phase 2 Terminated

9 enrolled

Breast

Breast Neoplasms

NCT04762901 2022-04-26

LCI-BRE-MTN-NIR-001:Ph I Study of Niraparib in Combo With Standard Chemo in Metastatic Trip Neg Breast Cancer

Phase 1 Withdrawn

Breast

Breast Neoplasms

NCT04655183 2021-06-30

Study of M4344 in Combination With Niraparib

Phase 1/2 Withdrawn

Breast

Breast Neoplasms

NCT04764084 2021-02-21

Niraparib Combined With Anlotinib in Homologous Recombination Repair (HRR) Gene-mutated Advanced Solid Tumors

Phase 1 Unknown

52 enrolled

BreastGastrointestinal

Breast Neoplasms, Pancreatic Neoplasms, Cholangiocarcinoma